Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA
» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:MRK, NYSE:PFE, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVS.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland as a stock corporation (Aktiengesellschaft) with an indefinite duration. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. It is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals. Its broad portfolio includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices. It operates in the following segments: Innovative Medicines (formerly named Pharmaceuticals): Innovative patent-protected prescription medicines; Sandoz: Generic pharmaceuticals and biosimilars; and Alcon: Surgical and vision care products.

Ratios

vs
industry
vs
history
P/E(ttm) 27.99
NVSEF's P/E(ttm) is ranked lower than
51% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. NVSEF: 27.99 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 29.97
Current: 27.99
5.7
29.97
Forward P/E 15.87
NVSEF's Forward P/E is ranked lower than
52% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. NVSEF: 15.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.99
NVSEF's PE(NRI) is ranked higher than
50% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. NVSEF: 27.99 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.15
Current: 27.99
10.63
31.15
Price/Owner Earnings (ttm) 16.80
NVSEF's Price/Owner Earnings (ttm) is ranked higher than
76% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. NVSEF: 16.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVSEF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.71 Max: 23.92
Current: 16.8
7.18
23.92
P/B 2.40
NVSEF's P/B is ranked higher than
61% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. NVSEF: 2.40 )
Ranked among companies with meaningful P/B only.
NVSEF' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.95
Current: 2.4
1.69
3.95
P/S 3.79
NVSEF's P/S is ranked lower than
56% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. NVSEF: 3.79 )
Ranked among companies with meaningful P/S only.
NVSEF' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.27 Max: 5.01
Current: 3.79
1.89
5.01
PFCF 22.79
NVSEF's PFCF is ranked higher than
50% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. NVSEF: 22.79 )
Ranked among companies with meaningful PFCF only.
NVSEF' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 17.11 Max: 26.68
Current: 22.79
7.05
26.68
POCF 16.29
NVSEF's POCF is ranked higher than
55% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. NVSEF: 16.29 )
Ranked among companies with meaningful POCF only.
NVSEF' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.26 Max: 19.3
Current: 16.29
5.77
19.3
EV-to-EBIT 24.41
NVSEF's EV-to-EBIT is ranked lower than
57% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. NVSEF: 24.41 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27
Current: 24.41
8.5
27
EV-to-EBITDA 14.11
NVSEF's EV-to-EBITDA is ranked higher than
63% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. NVSEF: 14.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.1
Current: 14.11
7.3
18.1
Shiller P/E 16.01
NVSEF's Shiller P/E is ranked higher than
89% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 47.37 vs. NVSEF: 16.01 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s Shiller P/E Range Over the Past 10 Years
Min: 9.68  Med: 14.69 Max: 21.57
Current: 16.01
9.68
21.57
Current Ratio 1.12
NVSEF's Current Ratio is ranked lower than
83% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. NVSEF: 1.12 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.4 Max: 2.83
Current: 1.12
0.96
2.83
Quick Ratio 0.84
NVSEF's Quick Ratio is ranked lower than
81% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. NVSEF: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.48
Current: 0.84
0.7
2.48
Days Inventory 135.81
NVSEF's Days Inventory is ranked lower than
60% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. NVSEF: 135.81 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 135.81
117.82
183.45
Days Sales Outstanding 62.61
NVSEF's Days Sales Outstanding is ranked higher than
61% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. NVSEF: 62.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 62.61
56.31
70.59
Days Payable 104.96
NVSEF's Days Payable is ranked higher than
70% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. NVSEF: 104.96 )
Ranked among companies with meaningful Days Payable only.
NVSEF' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 104.96
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.52
NVSEF's Dividend Yield is ranked higher than
91% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. NVSEF: 3.52 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s Dividend Yield Range Over the Past 10 Years
Min: 1.49  Med: 3.35 Max: 5.11
Current: 3.52
1.49
5.11
Dividend Payout 0.95
NVSEF's Dividend Payout is ranked higher than
69% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. NVSEF: 0.95 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s Dividend Payout Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.97
Current: 0.95
0.4
0.97
Dividend Growth (3y) 7.60
NVSEF's Dividend Growth (3y) is ranked lower than
54% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. NVSEF: 7.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVSEF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 7.15 Max: 18.5
Current: 7.6
0
18.5
Forward Dividend Yield 3.60
NVSEF's Forward Dividend Yield is ranked higher than
85% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. NVSEF: 3.60 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.56
NVSEF's Yield on cost (5-Year) is ranked higher than
88% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. NVSEF: 4.56 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.92  Med: 4.32 Max: 6.58
Current: 4.56
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVSEF's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. NVSEF: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVSEF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.32
NVSEF's Price/Tangible Book is ranked lower than
91% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. NVSEF: 14.32 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.68  Med: 5.26 Max: 35.21
Current: 14.32
2.68
35.21
Price/Projected FCF 1.23
NVSEF's Price/Projected FCF is ranked higher than
81% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. NVSEF: 1.23 )
Ranked among companies with meaningful Price/Projected FCF only.
NVSEF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.16 Max: 2.39
Current: 1.23
0.76
2.39
Price/Median PS Value 1.16
NVSEF's Price/Median PS Value is ranked lower than
53% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. NVSEF: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.12 Max: 1.61
Current: 1.16
0.72
1.61
Price/Graham Number 4.23
NVSEF's Price/Graham Number is ranked lower than
79% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. NVSEF: 4.23 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s Price/Graham Number Range Over the Past 10 Years
Min: 1.24  Med: 2.48 Max: 6.59
Current: 4.23
1.24
6.59
Earnings Yield (Greenblatt) (%) 4.08
NVSEF's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. NVSEF: 4.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVSEF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 4.08
3.7
11.8
Forward Rate of Return (Yacktman) (%) 4.79
NVSEF's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. NVSEF: 4.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVSEF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 13.8 Max: 61.6
Current: 4.79
1
61.6

More Statistics

Revenue (TTM) (Mil) $49,436
EPS (TTM) $ 2.80
Beta0.84
Short Percentage of Float0.00%
52-Week Range $66.35 - 83.80
Shares Outstanding (Mil)2,374.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,460 52,434 54,894
EPS ($) 4.77 5.26 5.84
EPS w/o NRI ($) 4.77 5.26 5.84
EPS Growth Rate
(3Y to 5Y Estimate)
3.38%
Dividends Per Share ($) 2.85 3.03 3.18
» More Articles for NVSEF

Headlines

Articles On GuruFocus.com
Novartis Has Bright Future Feb 01 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
7 Stocks With Low P/S Ratios Jan 11 2017 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 
A Double Dose of Trouble at Novartis Sep 22 2016 

More From Other Websites
[$$] Big pharma bets billions on 'silent' liver disease Feb 21 2017
Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education Feb 14 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Why the Majority of Analysts Deem Novartis a ‘Buy’ Feb 03 2017
Novartis’s Financial Guidance and Priorities for 2017 Feb 03 2017
Novartis’s Recent Developments Feb 02 2017
Novartis (NVS) Votubia Gets EU Approval for Label Expansion Feb 02 2017
Inside Novartis’s Eye Care Performance in 4Q16 Feb 02 2017
Novartis Has Bright Future Feb 01 2017
Novartis’s Innovative Medicines Segment in 4Q16 Feb 01 2017
Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16 Feb 01 2017
Novartis’s 4Q16 Earnings Meet Analysts’ Estimates Feb 01 2017
Novartis Considers Alcon Spin-Off Jan 31 2017
Trump pushes drugmakers for lower prices, more U.S. production Jan 31 2017
Novartis CEO to meet Trump along other drug industry executives Jan 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK